Abeona Therapeutics Inc (NASDAQ:ABEO) Sellers Reduced Their Shorts By 2.22% As Of Dec 8, 2018

Abeona Therapeutics Inc. (NASDAQ:ABEO) Corporate Logo

Change of 2.22% for Abeona Therapeutics Inc (NASDAQ:ABEO)’s shorted shares was recorded. It was announced in December by FINRA the 11.96M shorted shares on ABEO. The 12.23 million previous shares are down with 2.22%. 27 days will cost ABEO with 439,600 average volume to restore its former position. 40.81% is Abeona Therapeutics Inc float short.

The stock increased 4.79% or $0.39 during the last trading session, reaching $8.54.Abeona Therapeutics Inc. has 1.12 million shares volume, 71.21% up from normal. ABEO is uptrending and has moved 5.07% since December 8, 2017. ABEO underperformed by 10.55% the S&P500.

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy and plasma products for severe and life-threatening rare diseases.The company has $409.45 million market cap. The companyÂ’s lead programs are ABO-101, an adeno-associated virus based gene therapies for Sanfilippo syndrome type B; and ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A.Currently it has negative earnings. It is also developing EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); EB-201 for for epidermolysis bullosa (EB); ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; ABO-301, an AAV gene therapy for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9 gene editing approach to gene therapy program for rare blood diseases.

Abeona Therapeutics Inc. (NASDAQ:ABEO) Ratings Coverage

Total analysts of 3 have positions in Abeona Therapeutics (NASDAQ:ABEO) as follows: 3 rated it a “Buy”, 0 with “Sell” and 0 with “Hold”. The positive are 100%. Since June 27, 2018 according to StockzIntelligence Inc Abeona Therapeutics has 3 analyst reports. On Tuesday, November 13 the firm has “Buy” rating by Citigroup given.

For more Abeona Therapeutics Inc. (NASDAQ:ABEO) news brought out recently go to: Seekingalpha.com, Seekingalpha.com, Globenewswire.com, Fool.com or Benzinga.com. The titles are as follows: “Abeona Therapeutics: The Approval Pathway – Seeking Alpha” brought out on August 02, 2018, “Abeona Therapeutics announces two new appointments – Seeking Alpha” on October 18, 2018, “Abeona Therapeutics Reports Fourth Quarter 2017 Financial Results and Business Highlights – GlobeNewswire” with a publish date: March 16, 2018, “3 Biotech Stocks That Soared This Week: Are They Buys? – The Motley Fool” and the last “Daily Biotech Pulse: Viking’s Fatty Liver And Cholesterol Drug, Cyclacel Loss Narrows, Eton’s Debut – Benzinga” with publication date: November 13, 2018.

Abeona Therapeutics Inc. (NASDAQ:ABEO) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.